Dicerna Pharmaceuticals Inc (DRNA) is around the top of the Biotechnology industry according to InvestorsObserver. DRNA received an overall rating of 54, which means that it scores higher than 54 percent of all stocks. Dicerna Pharmaceuticals Inc also achieved a score of 84 in the Biotechnology industry, putting it above 84 percent of Biotechnology stocks. Biotechnology is ranked 99 out of the 148 industries.
What do These Ratings Mean?
Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.
What's Happening With Dicerna Pharmaceuticals Inc Stock Today?
Dicerna Pharmaceuticals Inc (DRNA) stock has fallen -3.87% while the S&P 500 is higher by 0.46% as of 11:34 AM on Wednesday, Apr 21. DRNA is down -$1.18 from the previous closing price of $30.46 on volume of 235,224 shares. Over the past year the S&P 500 is higher by 51.80% while DRNA is higher by 38.44%. DRNA lost -$1.52 per share the over the last 12 months.
Click Here to get the full Stock Score Report on Dicerna Pharmaceuticals Inc (DRNA) Stock.
